$-1.30
(Market cap
$3,131 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.7
-
Debt to Equity
0
-
Book Value
$4.6
-
EPS
$-2.6
-
Face value
--
-
Shares outstanding
113,577,629
6 Years Aggregate
CFO
$-83.62 Mln
EBITDA
$-198.19 Mln
Net Profit
$-204.30 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunome Inc (IMNM)
| 28.4 | 22.1 | 24.7 | 177.1 | 63.9 | 14.0 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Immunome Inc (IMNM)
| 102.3 | -0.7 | 384.2 | -82.9 | 33.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunome Inc (IMNM)
|
27.6 | 3,131.3 | 0.0 | -254.3 | -- | -43.9 | -- | 6.2 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Immunome Inc (IMNM)
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset... comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Read more
-
President, CEO & Chairman
Dr. Clay B. Siegall Ph.D.
-
President, CEO & Chairman
Dr. Clay B. Siegall Ph.D.
-
Headquarters
Bothell, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immunome Inc (IMNM)
What is the current share price of Immunome Inc (IMNM) Today?
The share price of Immunome Inc (IMNM) is $27.57 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Immunome Inc (IMNM) has given a return of 63.92% in the last 3 years.
What is the current PB & PE ratio of Immunome Inc (IMNM)?
Since, TTM earnings of Immunome Inc (IMNM) is negative, P/E ratio is not available.
The P/B ratio of Immunome Inc (IMNM) is 6.25 times as on 28-Aug-2026, a 21 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-8.83 |
2.96 |
2024 |
-2.27 |
3.68 |
2023 |
-2.20 |
1.96 |
2022 |
-0.73 |
1.61 |
2021 |
-6.26 |
3.21 |
What is the 52 Week High and Low of Immunome Inc (IMNM)?
The 52-week high and low of Immunome Inc (IMNM) are Rs 30.06 and Rs 8.67 as of 31-Aug-2026.
What is the market cap of Immunome Inc (IMNM)?
Immunome Inc (IMNM) has a market capitalisation of $ 3,131 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Immunome Inc (IMNM)?
Before investing in Immunome Inc (IMNM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.